SurModics, Inc.
Eden Prairie, MN 55344
Share:
SurModics' New Low Friction, Low Particulate Device Coatings Introduced
SurModics Serene™ hydrophilic coatings address unmet need for lubricious, low particulate medical device coatings EDEN PRAIRIE, Minn.--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification for medical devices, today introduced SurModics Serene™ lubricious coatings for endovascular medical devices. Serene coatings are a breakthrough technology that delivers lubricity and...
Read More »Surmodics to Host Virtual Annual Meeting of Shareholders
Virtual Meeting on February 11 at 4 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Thursday, February 11, at 4:00 p.m. CT (5:00 p.m. ET), as a virtual meeting. Gary Maharaj, chief executive officer, and Sue Knight,...
Read More »Surmodics Names Nusrath Sultana, MD, as Vice President, Clinical Affairs
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Nusrath Sultana, MD, has joined Surmodics as Vice President, Clinical Affairs, effective February 3, 2020. “We are fortunate to have someone of Nusrath’s caliber joining the Surmodics team,” said Gary...
Read More »Surmodics Completes Enrollment in Pivotal TRANSCEND Clinical Trial
Study designed to evaluate safety, efficacy of the company’s next-generation SurVeil™ drug-coated balloon Company Raises 2019 Revenue and EPS Guidance Eden Prairie, Minn.-- (Business Wire) -- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has completed enrollment in TRANSCEND, its pivotal...
Read More »Surmodics Provides Update Regarding TRANSCEND Clinical Trial
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, has resumed patient enrollment into its TRANSCEND clinical trial and is nearly 75 percent of the way to its goal of 446 randomized patients. Patient enrollment in TRANSCEND, the pivotal clinical trial for the SurVeil™...
Read More »Surmodics Names Teri Sides as Chief Marketing Officer
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Teri Sides has joined Surmodics as Senior Vice President and Chief Marketing Officer, effective November 1, 2018. I am thrilled to welcome Teri to our internal team. Teri has been an important contributor to...
Read More »Surmodics Announces Leadership Change and Appointment of Interim CFO
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Andrew LaFrence will resign as Chief Financial Officer (CFO) effective May 25, 2018. Following LaFrence’s departure, Timothy J. Arens, Vice President of Corporate Development and Strategy, will serve as...
Read More »Surmodics Acquires Thrombectomy Technology Assets from Embolitech, Strengthening Peripheral Vascular Whole-Product Solutions Portfolio
Surmodics’ design, development, hydrophilic coating technology and manufacturing capabilities will advance innovative platform technology EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today it has reached an agreement with Embolitech to acquire an innovative...
Read More »Surmodics to Host Virtual Annual Meeting of Shareholders
Virtual Meeting on February 21 at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. - Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Wednesday, February 21, at 4:00 p.m. CT (5:00 p.m. ET), as a virtual meeting. Gary Maharaj, chief executive officer, and Sue Knight, chair of the...
Read More »SurModics Acquires NorMedix, a Design and Development Company Focused on Minimally Invasive Catheter Technologies
• Furthers transformation strategy with vascular expertise and RD capabilities • Brings unique catheter-based technology and development capabilities • Raising revenue guidance to adjusted range of $62 million to $66 million • GAAP EPS in range of $0.30 to $0.35 per share; non-GAAP EPS unchanged at $0.66 to $0.75 per share EDEN PRAIRIE, Minn.Ã- – SurModics, Inc. (Nasdaq:SRDX), a...
Read More »SurModics Acquires Creagh Medical, a Developer and Manufacturer of Balloon Catheters
Accelerates strategic transformation into a whole-product solutions provider Significantly advances company’s drug-coated balloon development and manufacturing capabilities Expands pipeline of product development opportunities EDEN PRAIRIE, Minn. - SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has acquired Creagh...
Read More »